Pre-market Movers: BCAN, REUN, FOXO, ETNB, INO…

us pre market 053119 19sep22 lt

The following are some of the stocks making big moves in Monday's pre-market trading (as of 06.45 A.M. ET).

In the Green

BYND Cannasoft Enterprises Inc. (BCAN) is up over 309% at $17
Reunion Neuroscience Inc. (REUN) is up over 88% at $4.64
FOXO Technologies Inc. (FOXO) is up over 62% at $6.52
Inovio Pharmaceuticals, Inc. (INO) is up over 21% at $2.34
Senti Biosciences, Inc. (SNTI) is up over 21% at $1.95
Edgio, Inc. (EGIO) is up over 19% at $3.74
bluebird bio, Inc. (BLUE) is up over 15% at $7.31
Amprius Technologies, Inc. (AMPX) is up over 10% at $9.20

In the Red

89bio, Inc. (ETNB) is down over 27% at $4.56
Innate Pharma S.A. (IPHA) is down over 14% at $2.63
Valneva SE (VALN) is down over 11% at $14.27
FLEX LNG Ltd. (FLNG) is down over 7% at $29.86
Nano Labs Ltd (NA) is down over 7% at $5.17
Borr Drilling Limited (BORR) is down over 7% at $3.60
Frontline Ltd. (FRO) is down over 6% at $11.96
Take-Two Interactive Software, Inc. (TTWO) is down over 5% at $117.25
Intellinetics, Inc. (INLX) is down over 5% at $4.29

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Health insurer Humana Inc. reported Wednesday a net loss for the fourth quarter that slightly widened from last year, hurt primarily by charges associated with productivity initiatives, despite 6.6 percent revenue growth. Adjusted earnings for the quarter topped analysts' expectations, while quarterly revenues missed it by a whisker. South Plainfield, New Jersey-based Two Rivers Coffee is recalling its peanut butter single serve hot chocolate pods citing an undeclared peanut allergen, the U.S. Food Drug Administration said. The recall involves peanut butter single serve hot chocolate pods distributed as "Brooklyn Bean Peanut Butter Cup Hot Cocoa", "Pingo Peanut Butter Cookie Hot Chocolate" and ... Shares of Novartis AG were losing around 2 percent in the early morning trading in Switzerland after the drug major reported Wednesday sharply lower profit in its fourth quarter with weak sales as well as the absence of prior year's hefty Roche income. Adjusted earnings, however, topped market estimates, while top line missed their view. Further, the company announced higher dividend...
Follow RTT